Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity. / Raju, Sajan C.; Molinaro, Antonio; Awoyemi, Ayodeji; Jørgensen, Silje F.; Braadland, Peder R.; Nendl, Andraz; Seljeflot, Ingebjørg; Ueland, Per M.; McCann, Adrian; Aukrust, Pål; Vestad, Beate; Mayerhofer, Cristiane; Broch, Kaspar; Gullestad, Lars; Lappegård, Knut T.; Halvorsen, Bente; Kristiansen, Karsten; Hov, Johannes R.; Trøseid, Marius.

In: Genome Medicine, Vol. 16, No. 1, 27, 2024.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Raju, SC, Molinaro, A, Awoyemi, A, Jørgensen, SF, Braadland, PR, Nendl, A, Seljeflot, I, Ueland, PM, McCann, A, Aukrust, P, Vestad, B, Mayerhofer, C, Broch, K, Gullestad, L, Lappegård, KT, Halvorsen, B, Kristiansen, K, Hov, JR & Trøseid, M 2024, 'Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity', Genome Medicine, vol. 16, no. 1, 27. https://doi.org/10.1186/s13073-024-01296-6

APA

Raju, S. C., Molinaro, A., Awoyemi, A., Jørgensen, S. F., Braadland, P. R., Nendl, A., Seljeflot, I., Ueland, P. M., McCann, A., Aukrust, P., Vestad, B., Mayerhofer, C., Broch, K., Gullestad, L., Lappegård, K. T., Halvorsen, B., Kristiansen, K., Hov, J. R., & Trøseid, M. (2024). Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity. Genome Medicine, 16(1), [27]. https://doi.org/10.1186/s13073-024-01296-6

Vancouver

Raju SC, Molinaro A, Awoyemi A, Jørgensen SF, Braadland PR, Nendl A et al. Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity. Genome Medicine. 2024;16(1). 27. https://doi.org/10.1186/s13073-024-01296-6

Author

Raju, Sajan C. ; Molinaro, Antonio ; Awoyemi, Ayodeji ; Jørgensen, Silje F. ; Braadland, Peder R. ; Nendl, Andraz ; Seljeflot, Ingebjørg ; Ueland, Per M. ; McCann, Adrian ; Aukrust, Pål ; Vestad, Beate ; Mayerhofer, Cristiane ; Broch, Kaspar ; Gullestad, Lars ; Lappegård, Knut T. ; Halvorsen, Bente ; Kristiansen, Karsten ; Hov, Johannes R. ; Trøseid, Marius. / Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity. In: Genome Medicine. 2024 ; Vol. 16, No. 1.

Bibtex

@article{fb40b5c5d87e4c91a6b785a2956c5e3d,
title = "Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity",
abstract = "BACKGROUND: Interactions between the gut microbiota, diet, and host metabolism contribute to the development of cardiovascular disease, but a firm link between disease-specific gut microbiota alterations and circulating metabolites is lacking. METHODS: We performed shot-gun sequencing on 235 samples from 166 HF patients and 69 healthy control samples. Separate plasma samples from healthy controls (n = 53) were used for the comparison of imidazole propionate (ImP) levels. Taxonomy and functional pathways for shotgun sequencing data was assigned using MetaPhlAn3 and HUMAnN3 pipelines. RESULTS: Here, we show that heart failure (HF) is associated with a specific compositional and functional shift of the gut microbiota that is linked to circulating levels of the microbial histidine-derived metabolite ImP. Circulating ImP levels are elevated in chronic HF patients compared to controls and associated with HF-related gut microbiota alterations. Contrary to the microbiota composition, ImP levels provide insight into etiology and severity of HF and also associate with markers of intestinal permeability and systemic inflammation. CONCLUSIONS: Our findings establish a connection between changes in the gut microbiota, the presence, etiology, and severity of HF, and the gut-microbially produced metabolite ImP. While ImP appears promising as a circulating biomarker reflecting gut dysbiosis related to HF, further studies are essential to demonstrate its causal or contributing role in HF pathogenesis. TRIAL REGISTRATION: NCT02637167, registered December 22, 2015.",
keywords = "Gut microbiota, Heart failure, Imidazole propionate, Inflammation",
author = "Raju, {Sajan C.} and Antonio Molinaro and Ayodeji Awoyemi and J{\o}rgensen, {Silje F.} and Braadland, {Peder R.} and Andraz Nendl and Ingebj{\o}rg Seljeflot and Ueland, {Per M.} and Adrian McCann and P{\aa}l Aukrust and Beate Vestad and Cristiane Mayerhofer and Kaspar Broch and Lars Gullestad and Lappeg{\aa}rd, {Knut T.} and Bente Halvorsen and Karsten Kristiansen and Hov, {Johannes R.} and Marius Tr{\o}seid",
note = "Publisher Copyright: {\textcopyright} 2024. The Author(s).",
year = "2024",
doi = "10.1186/s13073-024-01296-6",
language = "English",
volume = "16",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity

AU - Raju, Sajan C.

AU - Molinaro, Antonio

AU - Awoyemi, Ayodeji

AU - Jørgensen, Silje F.

AU - Braadland, Peder R.

AU - Nendl, Andraz

AU - Seljeflot, Ingebjørg

AU - Ueland, Per M.

AU - McCann, Adrian

AU - Aukrust, Pål

AU - Vestad, Beate

AU - Mayerhofer, Cristiane

AU - Broch, Kaspar

AU - Gullestad, Lars

AU - Lappegård, Knut T.

AU - Halvorsen, Bente

AU - Kristiansen, Karsten

AU - Hov, Johannes R.

AU - Trøseid, Marius

N1 - Publisher Copyright: © 2024. The Author(s).

PY - 2024

Y1 - 2024

N2 - BACKGROUND: Interactions between the gut microbiota, diet, and host metabolism contribute to the development of cardiovascular disease, but a firm link between disease-specific gut microbiota alterations and circulating metabolites is lacking. METHODS: We performed shot-gun sequencing on 235 samples from 166 HF patients and 69 healthy control samples. Separate plasma samples from healthy controls (n = 53) were used for the comparison of imidazole propionate (ImP) levels. Taxonomy and functional pathways for shotgun sequencing data was assigned using MetaPhlAn3 and HUMAnN3 pipelines. RESULTS: Here, we show that heart failure (HF) is associated with a specific compositional and functional shift of the gut microbiota that is linked to circulating levels of the microbial histidine-derived metabolite ImP. Circulating ImP levels are elevated in chronic HF patients compared to controls and associated with HF-related gut microbiota alterations. Contrary to the microbiota composition, ImP levels provide insight into etiology and severity of HF and also associate with markers of intestinal permeability and systemic inflammation. CONCLUSIONS: Our findings establish a connection between changes in the gut microbiota, the presence, etiology, and severity of HF, and the gut-microbially produced metabolite ImP. While ImP appears promising as a circulating biomarker reflecting gut dysbiosis related to HF, further studies are essential to demonstrate its causal or contributing role in HF pathogenesis. TRIAL REGISTRATION: NCT02637167, registered December 22, 2015.

AB - BACKGROUND: Interactions between the gut microbiota, diet, and host metabolism contribute to the development of cardiovascular disease, but a firm link between disease-specific gut microbiota alterations and circulating metabolites is lacking. METHODS: We performed shot-gun sequencing on 235 samples from 166 HF patients and 69 healthy control samples. Separate plasma samples from healthy controls (n = 53) were used for the comparison of imidazole propionate (ImP) levels. Taxonomy and functional pathways for shotgun sequencing data was assigned using MetaPhlAn3 and HUMAnN3 pipelines. RESULTS: Here, we show that heart failure (HF) is associated with a specific compositional and functional shift of the gut microbiota that is linked to circulating levels of the microbial histidine-derived metabolite ImP. Circulating ImP levels are elevated in chronic HF patients compared to controls and associated with HF-related gut microbiota alterations. Contrary to the microbiota composition, ImP levels provide insight into etiology and severity of HF and also associate with markers of intestinal permeability and systemic inflammation. CONCLUSIONS: Our findings establish a connection between changes in the gut microbiota, the presence, etiology, and severity of HF, and the gut-microbially produced metabolite ImP. While ImP appears promising as a circulating biomarker reflecting gut dysbiosis related to HF, further studies are essential to demonstrate its causal or contributing role in HF pathogenesis. TRIAL REGISTRATION: NCT02637167, registered December 22, 2015.

KW - Gut microbiota

KW - Heart failure

KW - Imidazole propionate

KW - Inflammation

U2 - 10.1186/s13073-024-01296-6

DO - 10.1186/s13073-024-01296-6

M3 - Journal article

C2 - 38331891

AN - SCOPUS:85184794415

VL - 16

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 1

M1 - 27

ER -

ID: 382994526